
## PHARMACEUTICAL 2022



## PROVECTUS BIOPHARMACEUTICALS INC. Rank 417 of 475





## RealRate PHARMACEUTICAL 2022 PROVECTUS BIOPHARMACEUTICALS INC. Rank 417 of 475

The relative strengths and weaknesses of PROVECTUS BIOPHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PROVECTUS BIOPHARMACEUTICALS INC. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 318% points. The greatest weakness of PROVECTUS BIOPHARMACEUTICALS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 173% points.

The company's Economic Capital Ratio, given in the ranking table, is -483%, being 207% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	3,442
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,701
Liabilities, Non-Current	0
Other Assets	40
Other Compr. Net Income	-0.37
Other Expenses	0
Other Liabilities	0
Other Net Income	-867
Property and Equipment	32
Research and Development	2,608
Revenues	0
Selling, General and Administrative Expense	2,064

Output Variable	Value in 1000 USD
Assets	3,513
Liabilities	7,701
Expenses	4,672
Stockholders Equity	-4,187
Net Income	-5,540
Comprehensive Net Income	-5,540
Economic Capital Ratio	-483%

